Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
PremiumPress ReleasesAcumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
2M ago
Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference
PremiumPress Releases
Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference
3M ago
Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease
PremiumPress Releases
Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease
3M ago
Acumen presents first clinical, biomarker data for ACU193
PremiumThe FlyAcumen presents first clinical, biomarker data for ACU193
3M ago
Acumen  teams with Lonza for advancement of sabirnetug to treat AD
PremiumThe Fly
Acumen teams with Lonza for advancement of sabirnetug to treat AD
4M ago
Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease
PremiumPress Releases
Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease
4M ago
Acumen reports 2023 EPS ($1.08), consensus ($1.07)
PremiumThe FlyAcumen reports 2023 EPS ($1.08), consensus ($1.07)
4M ago
ABOS Earnings this Week: How Will it Perform?
PremiumPre-Earnings
ABOS Earnings this Week: How Will it Perform?
4M ago
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024
PremiumPress Releases
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100